NCT00920257 2017-11-13A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795GlaxoSmithKlinePhase 1 Completed77 enrolled
NCT01138085 2017-11-13Safety, Pharmacokinetics (PK) of AKT and MEK CombinationGlaxoSmithKlinePhase 1 Completed240 enrolled